Luciana Molinero to Patient Reported Outcome Measures
This is a "connection" page, showing publications Luciana Molinero has written about Patient Reported Outcome Measures.
Connection Strength
0.050
-
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023 10; 177:20-31.
Score: 0.050